Background: Lymphopenia is a predictive factor for hematological toxicity, progression and early death in advanced cancers including metastatic breast cancer (MBC). CYT107 is a recombinant interleukin 7 (IL-7) (Cytheris, now Revimmune), well tolerated and able to expand lymphocyte pool in humans. The aims of this study were to determine the optimal schedule to deliver CYT107 and to assess its effect on clinical end points.
shown that lymphopenia is observed in 20% of patients with advanced cancers including metastatic breast cancer (MBC). Lymphopenia is correlated to higher risk of severe hematological toxicity [1, [5] [6] [7] . All lymphocyte compartments are affected including CD4 + and CD8 + T, NK and B lymphocytes. Of importance, CD4 + T-cell deficit, detected before the initiation of chemotherapy, is predictive of early death and poor survival [6, [8] [9] [10] [11] . To date, it remains unknown whether a treatment can restore a normal T-cell pool and whether such immune reconstitution could translate into clinical benefit in advanced cancer patients.
IL-7 is a multifunctional lymphopoietic cytokine that plays critical roles in T-cell development, expansion, function and protection from apoptosis [12] [13] [14] [15] . First, IL-7 contributes to immune reconstitution through the expansion of T cells, the support of thymopoïesis, the induction of chemokine and chemokine receptors and its direct trophic effect on lymphoid tissues. Second, IL-7 contributes to the restoration of dysfunctional immune responses by inhibiting both the production and the downstream postreceptor signaling of transforming growth factor-β [16] and the functional enhancement of αβ-T-cell reactivity to weak immunogens, such as tumorassociated antigens. In vivo, IL-7 exerts antitumor effects by enhancing immune response against tumors, especially when combined with chemotherapy [15, [17] [18] [19] . CYT107 (Cytheris, now Revimmune) is a glycosylated recombinant human IL-7 [19, 20] . Clinical trials conducted on more than 220 patients [mainly human immunodeficiency virus (HIV), hepatitis C or B virus-infected patients] have demonstrated that repeated doses of CYT107 induced a dose-dependent and sustained expansion of CD4 + and CD8 + T-cells subsets. Overall, CYT107 was well tolerated; the most frequent side-effects were injection site reactions, lymphadenopathy, fever, rash and fatigue [15, [20] [21] [22] [23] [24] .
The main objectives of this clinical trial were (i) to define the optimal schedule to deliver CYT107 based on its immunopharmacological effect on CD4 + T cells and (ii) to assess whether CYT107 treatment can reduce the incidence of severe hematological toxicity in lymphopenic MBC treated by standard chemotherapy.
patient and methods patients
Key inclusion criteria were: ≥18 years old, histologic or cytologic confirmed diagnosis of MBC to be treated with capecitabine, at least one value of lymphocyte count <1500/µl within 15 days before inclusion, Eastern Cooperative Oncology Group Performance Status ≤3, adequate bone marrow, hepatic and renal functions. Exclusion criteria included: significant medical conditions, especially history of immune dysfunction, lymphoid malignancy and concomitant steroid treatment.
The study was conducted in accordance with the principles of Good Clinical Practice, as defined by the International Conference on Harmonization. The study protocol was approved by the institutional review board of Centre Léon Bérard in Lyon and an Ethic Committee (CCP Sud-Est IV, Lyon, France). A written informed consent was obtained from each patient before study enrollment.
study design
Using a 2-by-2 factorial design [25] , 20 MBC patients were allocated into one of the four study arms to receive ( Figure 1A ): arm 1: placebo before (D0, D7, D14) and during chemotherapy (D57, D64, D71); arm 2: CYT107 before chemotherapy and placebo during chemotherapy; arm 3: placebo before chemotherapy and CYT107 during chemotherapy; arm 4: CYT107 before and during chemotherapy. CYT107 was administrated s.c. at the dose of 10 µg/kg/ week for 3 consecutive weeks (first CYT107/placebo cycle at D0, D7, D14 and second CYT107/placebo cycle at D57, D64, D71) [21, 22] . The second cycle of CYT107/placebo was initiated only if immunogenicity assays (carried out on D42 plasma sampling) were negative and lymphocyte count was <2000/µl. Chemotherapy consisted in capecitabine (1250 mg/m 2 /bi-daily, per os for 14 days over a 21-day cycle period) until progressive disease, unacceptable toxicity or patient willingness to stop. Granulocyte colony-stimulating factor was not used during the study period.
The sponsor, patients, medical and nonmedical staffs were blinded with respect to the patient's treatment assignment. However, an Independent Safety Monitoring Committee had the possibility to access unblinded data.
study end points and assessment
The primary study end point was the evolution of the CD4 + lymphocyte count, assessed as relative evolution (i.e. percentage of changes) over the 21-day period of each CYT107/placebo cycle administered either before (i.e. from D0 to D21) or during (i.e. from D57 to D78) chemotherapy. The choice to analyze these criteria as a relative change was guided by the high interpatient variability of CD4 + lymphocyte count at baseline (Table 1) . Secondary end points included (i) grade ≥3 hematological adverse events (AEs) according to the National Cancer Institute-Common Terminology Criteria (NCI-CTCAE) version 4.0 and overall AE incidence; (ii) best overall response, (iii) progression-free survival (PFS) and overall survival (OS).
clinical assessments. Tumor response was assessed using CT scans repeated every 3 months (or sooner if disease progression was suspected) and evaluated as per RECIST v1.1 (Response Evaluation Criteria in Solid Tumors version 1.1). PFS was defined as the time from randomization to progression or death from any cause. OS was defined as the time from randomization to death from any cause.
immuno-monitoring. Blood samples were withdrawn at baseline (D0), before (D21) and during (D57 and D78) chemotherapy and at the end of study visit (EOS 
statistical analysis
All patients receiving at least one dose of the study drug were included in the safety analyses. For efficacy end points, analyses were based on the intent-totreat population (all randomized patients). In accordance with the 2-by-2 factorial design, two main comparisons were carried out: (i) between patients having received CYT107 before chemotherapy (arms 2 and 4) or not (arms Figure 1B ). Differences in median relative evolution (percentage of changes from D0 to D21 and from D57 to D78, Figure 1A ) between groups were assessed by the Wilcoxon signed rank test.
PFS and OS were estimated according to time using the Kaplan-Meier method. Median follow-up was calculated using a reverse Kaplan-Meier estimate. Statistical analyses were carried out using the SAS software (version 9.3). Table 1 . All patients were lymphopenic at inclusion with a median CD4 + lymphocyte count of 242 cells/µl. The majority of patients had estrogen receptor (ER)-positive MBC. Most of the patients had bone (n = 16, 80%) or liver (n = 13, 65%) metastases. In the metastatic setting, 16 patients (80%) had been previously treated by chemotherapy and/or targeted therapy (mainly taxane ± bevacizumab) and 13 patients (65%) had received previous endocrine therapy.
All randomized patients received at least one dose of study drug ( placebo or CYT107) and were evaluable for safety. The reasons for early treatment discontinuation (n = 9) were: patient decision due to rapid disease progression and willingness to start chemotherapy; lymphocytes count >2000/µl before the second cycle of CYT107/placebo; disease progression and one case of fatal suspected unexpected serious adverse reaction (SUSAR; unexpected acute respiratory failure, Figure 1B ).
impact of CYT107 on immune cell subsets CYT107 induced a significant increase in T-cell population either before or during chemotherapy; while B lymphocytes, monocytes and NK absolute numbers were not significantly modified (supplementary Figure S1 , available at Annals of Oncology online). When administered before chemotherapy, CYT107 induced a significant increase in CD4 + T-cell count with a median relative evolution from D0 to D21 of +148.1% versus +9.9% for CYT107 and placebo groups, respectively (P = 0.002, Figure 2A ). When CYT107 was administrated during chemotherapy, CD4 + T-cell count increased with a lesser magnitude [+58.6% versus −2.4% for CYT107 and placebo groups, respectively (P = 0.121), Figure 2A ]. CYT107 increased both the naïve and memory CD4 + Taxol-based chemotherapy  3  4  5  3  15  Hormonotherapy  3  3  4  3 ) count [median relative increase at D21: +250.0% versus +60% in CYT107 and placebo groups, respectively (P = 0.017), Figure 4A ]. However, this increase remained transient [median relative increases from D0 to D57: +12.5% versus +7.5% in CYT107 and placebo groups, respectively (P = 0.784)] compared with CD4 + increase [median relative increases from D0 to D57: +57.4% versus +18.4% in CYT107 and placebo groups, respectively (P = 0.055), Figure 4A ]. When CYT107 was administrated during chemotherapy, there was no T reg increase.
Of importance, CYT107 treatment yielded functionally competent CD4
+ and CD8 + memory T-cell subsets as assessed by their capacity to secrete cytokine (IFN-γ, IL-2) after ex vivo reactivation ( Figure 4B ). Overall, CYT107 was well tolerated with no grade ≥3 AE related to study drug except one case of fatal acute respiratory failure of uncertain relationship (fatal SUSAR). The most frequently reported treatment-related AE were fever, fatigue, injection site reactions and nausea (Table 2A) . No anti-CYT107 antibodies were detected in sera (not shown). During chemotherapy, no patients receiving CYT107 reported severe hematological toxicities whereas two patients receiving placebo reported six severe hematological AEs (Table 2A) . No case of febrile neutropenia was reported. Of the 12 cases evaluable for tumor response, 6 of 7 patients (86%) receiving CYT107 before chemotherapy achieved an objective response or stabilization, whereas two of five patients (40%) receiving only placebo achieved the same result (Table 2B) . With a median follow-up of 14.7 (range: 1.1-21.6) months, no significant impact of CYT107 treatment was observed on PFS or OS (Figure 4 , T reg relative evolution from D0 to D21 T reg relative evolution from D0 to D57 T reg relative evolution from D57 to D78 Total CD4 + relative evolution from D0 to D57 
discussion
Prolonged CD4 + lymphopenia commonly occurs in advanced cancer patients and correlates with increased hematological toxicity and shorter survival [6, 9, 11] . In this trial, the administration of two cycles of recombinant IL-7 (CYT107) in lymphopenic MBC patients was safe and restored CD4 + and CD8 + T-cell numbers without altering their functionality. Before chemotherapy, CYT107 significantly enhanced naïve and memory CD4 + and CD8 + T cells, in accordance with prior observations in patients with advanced solid tumors [22, 24] . This is also consistent with the increase of memory CD8 + T-cell subsets previously reported in HIV-infected or allogeneic hematopoietic stem-cell transplantation patients exposed to CYT107 [22, 26] . Importantly, CYT107 did not affect other circulating immune cells such as B lymphocytes in agreement with their lack of IL-7Rα expression [27] and monocytes despite their IL-7Rα expression [28] . During chemotherapy, CYT107 expanded both CD4 + and CD8 + naïve and memory T-cell subsets, thus suggesting that although CYT107 induces T-cell cycling and may sensitize them to cytotoxic effect of chemotherapies; it is achievable to increase T-cell numbers during chemotherapy in advanced cancer patients. Interestingly, CYT107 yielded an [29] and to breast cancer progression [3, 30, 31] . When administered before chemotherapy, CYT107 enhanced T reg pool as recently reported [32] and consistently with the increased expression of IL-7Rα on T reg cell surface under activation [33] . Importantly, T reg increase was not sustained overtime. This contrasts with the effect of IL-2 treatment that sustained both T reg proliferation and suppressive function for up to 3 weeks after the completion of IL-2 treatment [34, 35] . Moreover, while IL-2 expands predominantly CD4 + T cells, thus increasing the CD4/ CD8 ratio [36] , our results demonstrated the ability of CYT107 to expand diverse CD4 + and CD8 + T-cell subpopulations, affecting both naïve or memory subsets, in line with previously reported results in the HIV. Such expansion of CD4 + T cells could result from both a stimulation of CD4 + T-cell proliferation and a reduction of apoptosis as well as an increase in recent thymic emigrants as previously described [22, 23, 37] .
Overall, CYT107 was well tolerated. Main AEs related to CYT107 were mild to moderate (no grade 3) and consisted essentially in fever and cutaneous reaction at injection site. These results confirm the previously reported safety profile of CYT107 in advanced cancer patients [24] . The favorable safety profile of CYT107, as opposed to severe toxicities described with IL-2 (hematological toxicities, capillary leak syndrome) [38, 39] , indicates that CYT107 is an interesting therapeutic option deserving further clinical investigations. Of note, during chemotherapy, no patient treated with CYT107 experienced severe hematological AE whereas two patients treated with placebo reported six severe hematological AEs. Although this preliminary result needs to be confirmed in larger randomized trials, this could be of clinical importance considering that chemotherapy is often modified, shortened or discontinued due to grade 4 neutropenia [1, 5, 7] .
The present study provides several arguments to define the optimal schedule to administer CYT107 in order to reach clinical efficacy in a larger randomized trial. First, CYT107 should be administered before the initiation of chemotherapy in order to induce significant reconstitution of T-cells pool. However, the interval between CYT107 treatment and the beginning of the chemotherapy should be as short as possible to minimize the period of time without specific anti-cancer treatment. Second, CYT107 should be administered with repeated cycles during chemotherapy in the objective to induce a sustained T-cell subsets increase as described in HIV patients [15] . Indeed, CYT107 effect on T-cell numbers was important but remained transient overtime and under repeated cycles of chemotherapy. This is in accordance with the recent mathematical analysis reported by Thiébaut et al. that underlines the importance of repeated cycles of IL-7 for long-term CD4 + T-cell response in HIV-infected patients [37] .
In conclusion, this study clearly shows that CYT107 is able to partially restore T-cell pool in lymphopenic cancer patients, increasing both naïve and memory CD4 + and CD8 + subsets with normal functional capacities. The impact of CYT107 on patient outcome needs to be further assessed in a randomized trial exploring CYT107 in a larger cohort of lymphopenic cancer patients.
